{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/79701"],"location":["China"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A two-arm, multicenter exploratory clinical study of anrotinib combined with piemprizumab and crapy in first-line treatment hemotheof metastatic colorectal cancer","description":"Interventions: Group A:Sequential therapy with arotinib, oxaliplatin, capecitabine, and paclitaxel;Group B:Simultaneous treatment with arotinib + oxaliplatin + capecitabine + paiampilizumab\nPrimary outcome(s): ORR\nStudy Design: Non randomized control","dates":{"creation":"2022-05-15"},"accession":"79701","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2200060634"]}}